Evidence map›Paper›PMID 38681670›Full record

ArticleBiochemistry and biophysics reports2024

Preparation of stable and monodisperse paclitaxel-loaded bovine serum albumin nanoparticles via intermolecular disulfide crosslinking.

Yusuke Kono, Tomoyuki Sugaya, Hikaru Yasudome, Hideo Ogiso, Ken-Ichi Ogawara

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yusuke KonoLaboratory of Pharmaceutics, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe, 658-8558, Japan.
Tomoyuki SugayaLaboratory of Pharmaceutics, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe, 658-8558, Japan.
Hikaru YasudomeLaboratory of Pharmaceutics, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe, 658-8558, Japan.
Hideo OgisoToyama Prefectural Institute for Pharmaceutical Research, 17-1 Nakataikoyama, Imizu, 939-0363, Japan.
Ken-Ichi OgawaraLaboratory of Pharmaceutics, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe, 658-8558, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paclitaxel (PTX) is one of the most used anti-cancer drugs worldwide. Due to its insolubility in water, the clinically available liquid formulation of PTX contains Cremophor EL that is responsible for severe hypersensitivity. Albumin-based nanoparticles have emerged as a promising carrier for anti-cancer drugs because albumin nanoparticles have high capacity to not only load lipophilic drugs without solubilizer but also accumulate in tumor by both passive and active mechanisms. In this study, we attempted to prepare solvent-free formulation of PTX-loaded bovine serum albumin (BSA) nanoparticles with high stability, and the

Indexed as

Albumin nanoparticleColloidal stabilityDisulfide crosslinkingPaclitaxel

Identifiers

PMID38681670
PMCPMC11047288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.